Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1098 - A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability


09 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


David Tougeron


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


D. Tougeron1, R. Cohen2, B. Sueur1, D. Sefrioui3, L. Gentilhomme3, T. Lecomte4, T. Aparicio5, G. Des Guetz6, P. Artru7, C. de la Fouchardiere8, V. Moulin9, V. Hautefeuille10, R. Coriat11, Y. Touchefeu12, C. Lecaille13, G. Goujon14, A. Ferru15, J. Taieb16, T. André2, A. Zaanan16

Author affiliations

  • 1 Gastroenterology, Poitiers university Hospital, 86000 - Poitiers/FR
  • 2 Medical Oncology, Hopital Saint Antoine, 75571 - Paris/FR
  • 3 Gastroenterology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 4 Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 5 Department Of Gastroenterology, CHU Saint Louis AP-HP, 75012 - Paris/FR
  • 6 Oncology, Saint Denis Hospital, 93200 - Saint Denis/FR
  • 7 Gastroenterology, Hôpital Privé Jean Mermoz, 69373 - Lyon/FR
  • 8 Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 9 Oncology, La Rochelle Hospital, 17000 - La Rochelle/FR
  • 10 Department Of Gastroenterology, CHU Amiens-Picardie Site Nord, 80054 - Amiens/FR
  • 11 Gastroenterology And Digestive Oncology, Hôpital Cochin, 75014 - PARIS/FR
  • 12 Imad, Department Of Gastroenterology, Nantes University Hospital, 44093 - Nantes/FR
  • 13 Department Of Oncology, Polyclinique Bordeaux Nord, Bordeaux/FR
  • 14 Oncology, Hopital Bichat Claude Bernard, 75018 - Paris/FR
  • 15 Medical Oncology, Poitiers university Hospital, 86000 - Poitiers/FR
  • 16 Department Of Gastroenterology And Digestive Oncology, Hôpital Européen Georges Pompidou, Paris/FR


Abstract 1098


Deficient Mismatch Repair (dMMR) and/or microsatellite instability-high colorectal cancers (CRC) represent 12% of all tumors. dMMR non-metastatic CRC are associated with good prognosis but also with resistance to adjuvant 5FU. dMMR metastatic CRC (mCRC) is found in 5% and its influence on prognosis and chemosensitivity is little known.


This multicenter study included patients with dMMR mCRC treated between 2005 and 2015 in 18 French centers. The Kaplan-Meier method was used to calculate overall survival (OS) and progression-free survival (PFS). Prognostic variables were evaluated in univariate (Log rank test) and multivariate analyses (Cox regression model).


284 patients with dMMR mCRC were included. Lynch syndrome was found in 43% and BRAF mutation in 32%. Median OS was 25.0 months. Peritoneal carcinomatosis (p 


This study suggests that dMMR mCRC are associated with poor prognosis with conventional chemotherapy with or without bevacizumab or anti-EGFR. Only surgery of metastasis was associated with better PFS.

Clinical trial identification

Legal entity responsible for the study

Tougeron David




D. Tougeron: Consulting or advisory role for Amgen, Sanofi, Celgene. Travel or accommodation from Ipsen, Amgen, Sanofi. J. Taieb: Honoraria: Amgen, Merck, Roche, Baxalta, Celgene, Sanofi, Lilly, Sirtex. T. André: Honoraria: Roche, Bms, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.